Final Report Summary - HIV Virosomes (DEVELOPMENT OF A NEW VACCINE AGAINST HIV: VIROSOMES INCORPORATING HIV PROTEINS)
A safe and effective vaccine is the only way to stop the spread of human immunodeficiency virus (HIV), especially in developing countries. Despite enormous efforts of numerous groups no convincing protective vaccine against HIV-1 has been generated so far. The objective of the 'Development of a new vaccine against HIV: virosomes incorporating HIV proteins' (HIV Virosomes) project was to develop a preventive HIV vaccine using a focused straight-forward approach. The aim was to incorporate native proteins derived from primary HIV strains into liposomes generated by a novel large scale liposomal technology. Alternatively, recombinant HIV proteins should be used. This project included:
- stabilisation of the native structure and conformation of native and recombinant HIV envelope proteins in liposomes
- selection of candidate vaccines in small animal immunisation studies;
- establishment of immunogenicity, and eventually, efficacy in the rhesus macaque model;
- establishment of a GMP compliant process suitable for production of clinical material.
- stabilisation of the native structure and conformation of native and recombinant HIV envelope proteins in liposomes
- selection of candidate vaccines in small animal immunisation studies;
- establishment of immunogenicity, and eventually, efficacy in the rhesus macaque model;
- establishment of a GMP compliant process suitable for production of clinical material.